Global Cancer Treatment Market
The global cancer treatment market was valued at $95bn in 2016 and is forecast to grow at a strong 7.2.% CAGR between 2018 and 2023, resulting in 2023 global sales of $155bn driven by targeted therapies & strong market uptake of a range of Immuno-Oncology (IO) treatments.
Worldwide, more than 14 million new cases of cancer are diagnosed each year and this number is expected to increase to 24 million by 2035. Global spending on cancer treatment increased to $100 billion from $75 five years earlier. Although improved screening technology is accelerating the diagnosis rate, there remains strong unmet need in cancer with limited and effective treatment options for many tumor types.
The most common types of cancers are lung, breast, colorectal and prostate, which together account for about 43% of new cases worldwide.
immunotherapy offer the promise of improved survival with lower toxicity for some patients. Leading marketed treatments include Bristol-Myers’ Yervoy and Opdivo, Merck’s Keytruda and Roche’s Tecentriq. Together, these drugs are approved for six different tumor types such as melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck cancer, bladder cancer and Hodgkin’s lymphoma.
Immunotherapy R&D Pipeline looks exciting with a number of promising experimental drugs with a wide range of indications including gastric cancer, Merkel cell carcinoma, colorectal cancer, hepatocellular carcinoma, triple negative breast cancer, multiple myeloma, glioblastoma and NHL. Another disruptive drug class that holds promise remains Anti-PD- 1/PD-L1. AstraZeneca, Pfizer, Eli Lilly, Novartis, Sanofi, Johnson & Johnson are actively developing drugs in this class.